ClinicalTrials.gg
CompletedNCT05106309Updated Apr 27, 2022

Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants

A Phase 1 interventional study of 10 mg CVL-231 as IR formulation and 30 mg CVL-231 as slow-release MR formulation in Schizophrenia, sponsored by Cerevel Therapeutics, LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-27.

Sponsored by Cerevel Therapeutics, LLC (part of AbbVie) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2022, 4 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies in Schizophrenia by AbbVie — 1 open to participants now, 1 under way, none of them phase 3. Schizophrenia · AbbVie.

Enrollment
26th of 27
16 · median 268
Started
2021
with 2 others
Phase 1
6 of 27
none open now
Registered
21st of 27
by date

Among the 27 studies in Schizophrenia by AbbVie, this one is the 26th largest by enrollment, is one of 3 that started in 2021, is one of 6 in phase 1, and was the 21st registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

1 of the 27 studies in Schizophrenia by AbbVie is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Schizophrenia by AbbVie, or all of them as a file.
02

Study summary

A 2-part, crossover design, open-label treatment trial with 4 periods, 4 sequences (Part A) to evaluate MR formulations of CVL-231 and a 2 periods, 2 sequences (Part B) to understand effect of food on CVL-231 exposures from an MR formulation.

Read the detailed description

CVL-231 is a muscarinic acetylcholine receptor (mAChR) activator that selectively binds to the M4 muscarinic receptor subtype (M4 mAChR) and is being developed for treatment of psychosis in schizophrenia. Part A of this 2-part trial will investigate the PK of CVL-231 in healthy participants following a single oral dose of CVL-231 as 3 modified-release (MR) formulations with different release rates and an immediate-release (IR) formulation under fasted conditions. Upon selection of an MR formulation with appropriate PK characteristics, the effect of food on the PK of CVL-231 and its metabolite following single oral doses of the selected MR formulation may be evaluated in Part B.

03

Conditions studied

  • Schizophrenia

Keywords

  • Schizophrenia
  • Healthy Volunteer
  • Schizophrenia Spectrum and Other Psychotic Disorders
  • Mental Disorders
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Women of nonchildbearing potential and men 18 to 55 years, inclusive.
  2. Healthy as determined by medical evaluation, including medical and psychiatric history, physical and neurological examinations, , vital sign measurements, and laboratory test results, as evaluated by the investigator.
  3. of 18.5 to 30.0 kg/m2 and a total body weight >50 kg (110 lbs).
  4. Sexually active men with a pregnant or a nonpregnant partner of must agree to comply with protocol requirements during treatment and through 7 days post dose. In addition, male participants should not donate sperm for a minimum of 7 days following the last dose of IMP.
  5. Capable of giving signed .
  6. Ability, in the opinion of the investigator, to understand the nature of the trial and comply with protocol requirements.

Exclusion criteria

Exclusion Criteria:

  1. Current history of significant cardiovascular, pulmonary, gastrointestinal, renal, hepatic, metabolic, endocrine, hematological, immunological, or neurological disease that, in the opinion of the investigator or medical monitor, could compromise either participant safety or the results of the trial.
  2. Current or past personal or family history of any psychiatric disorder as classified by criteria.
  3. Epilepsy or a history of seizures except for a single seizure episode, eg, a childhood febrile seizure, a seizure related to trauma or alcohol withdrawal, or an unexplained loss of consciousness.
  4. History of moderate to severe substance or alcohol-use disorder (excluding caffeine) within 12 months prior to signing the ICF.
  5. Serious risk of suicide in the opinion of the investigator
  6. Receipt of SARS-CoV2 vaccine or booster within 28 days of dosing with CVL-231, or plan to receive SARS-CoV2 vaccination or booster from Screening through 5 days after last dose of CVL-231.
  7. Have recently been diagnosed with symptomatic COVID-19 or test positive for COVID-19 within 30 days prior to signing the ICF.
  8. Either of the following:

    • History of , , or infection
    • Positive result for HIV antibody, hepatitis B surface antigen, hepatitis B core antibody, or hepatitis C antibody
  9. Positive drug screen for illicit drugs or a positive test for alcohol
  10. 12-lead demonstrating pre-defined abnormalities at Screening and Day -1 based on local evaluation.
  11. Abnormal clinical laboratory tests or vital sign measurements at the Screening Visit and at Day -1 (check-in) for each period
  12. Known to be allergic or hypersensitive to the IMP or any of its components.
  13. Participation in any clinical trial within 90 days prior to signing the ICF.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Part A: Single doses of CVL-231 IR/MR formulations in healthy participants under fasted conditions

    Oral Dose

    Drug: 10 mg CVL-231 as IR formulation · Drug: 30 mg CVL-231 as slow-release MR formulation · Drug: 30 mg CVL-231 as medium release MR formulation · Drug: 30 mg CVL-231 as fast release MR formulation

  • Experimental
    Part B: Single doses of CVL-231 target release formulation under fasted and fed conditions

    Oral Dose

    Drug: 30 mg CVL-231 Target Release, Fasted · Drug: 30 mg CVL-231 Target Release, Fed

Interventions

  • Drug10 mg CVL-231 as IR formulation

    Tablets

  • Drug30 mg CVL-231 as slow-release MR formulation

    Capsules

  • Drug30 mg CVL-231 as medium release MR formulation

    Capsules

  • Drug30 mg CVL-231 as fast release MR formulation

    Capsules

  • Drug30 mg CVL-231 Target Release, Fasted

    Capsules

  • Drug30 mg CVL-231 Target Release, Fed

    Capsules

06

What researchers measure

Primary outcomes

  1. Primary Part A & B: Peak Plasma Concentration (Cmax) for CVL-231 and Metabolite (CV-0000364)

    Time frame: Up to 72 Hours in each period

  2. Primary Part A & B: Time to Maximum Concentration (Tmax) for CVL-231 and Metabolite (CV-0000364)

    Time frame: Up to 72 Hours in each period

  3. Primary Part A & B: Time prior to the first measurable (non-zero) concentration (Tlag) for CVL-231 and Metabolite (CV-0000364)

    Time frame: Up to 72 Hours in each period

  4. Primary Part A & B: Area under the plasma concentration-time curve from time 0 to the last measurable time point (AUClast) for CVL-231 and Metabolite (CV-0000364)

    Time frame: Up to 72 Hours in each period

  5. Primary Part A & B: Area under the plasma concentration-time curve from time zero to infinity (AUCinf) for CVL-231 and Metabolite (CV-0000364)

    Time frame: Up to 72 Hours in each period

  6. Primary Part A & B: Elimination half-life (t½) for CVL-231 and Metabolite (CV-0000364)

    Time frame: Up to 72 Hours in each period

  7. Primary Part A only: Dose normalized Cmax, derived by Cmax divided by the dose administered (Cmax/D) for CVL-231 and Metabolite (CV-0000364)

    Time frame: Up to 72 Hours in each period

  8. Primary Part A only: Dose normalized AUClast, derived by AUClast divided by the dose administered (AUClast/D) for CVL-231 and Metabolite (CV-0000364)

    Time frame: Up to 72 Hours in each period

  9. Primary Part A only: Dose normalized AUCinf, derived by AUCinf divided by the dose administered (AUCinf/D) for CVL-231 and Metabolite (CV-0000364)

    Time frame: Up to 72 Hours in each period

Secondary outcomes

  1. Secondary: Incidence and Severity of Treatment Emergent Adverse Events (TEAEs)

    Time frame: Up to Day 14

  2. Secondary: Incidence of clinically significant changes in electrocardiogram (ECG) results

    Assessment of clinically significant changes in QT intervals measured by 12-lead ECG recording after the participant has been supine and at rest for at least 3 minutes.

    Time frame: Up to 72 Hours in each period

  3. Secondary: Incidence of clinically significant changes in clinical laboratory results

    Time frame: Up to 72 Hours in each period

  4. Secondary: Incidence of clinically significant changes in vital sign measurements

    Assessment of clinically significant changes in vital signs including temperature, systolic and diastolic blood pressure, and heart rate.

    Time frame: Up to 72 Hours in each period

  5. Secondary: Incidence of clinically significant changes in physical and neurological examination results

    Time frame: Up to 72 Hours in each period

  6. Secondary: Clinically significant findings in suicidality assessed using the Columbia Suicide-Severity Rating Scale (C-SSRS)

    The C-SSRS rates an individual's degree of suicidal ideation (SI) on a scale, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent." The scale identifies SI severity and intensity, which may be indicative of an individual's intent to commit suicide. C-SSRS SI severity subscale ranges from 0 (no SI) to 5 (active SI with plan and intent).

    Time frame: Up to 72 Hours in each period

07

Study locations

1 site
  • Celerion Inc.
    Tempe, Arizona 85283, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Feb 2022, 1 month.

Of 108 industry-sponsored phase 1 interventional studies under Schizophrenia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 1 month is below that.

Counting every sponsor, half of 133 studies reached it within 12 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2021
First posted
Nov 3, 2021
StartActual
Dec 29, 2021
Primary completionActual
Feb 24, 2022
CompletionActual
Feb 24, 2022
Last update
Apr 27, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05106309
Responsible party
Sponsor
First posted
Nov 3, 2021
Start date
Dec 29, 2021
Primary completion
Feb 24, 2022
Completion
Feb 24, 2022
Last update
Apr 27, 2022

Study contacts

Matthew Leoni, MD, MBA
study director · Cerevel Therapeutics, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion